|
| Thursday, 8 June 2017, 11:07 JST | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, June 8, 2017 - (JCN Newswire) - Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin), will be launched on June 8.
Lyrica Capsules are co-promoted in Japan by Pfizer and Eisai, with both companies working to provide information on its proper use. Likewise, Lyrica OD Tablets will also be co-promoted by both companies in Japan.
Lyrica is indicated for use in patients with neuropathic pain and pain associated with fibromyalgia. Many of these patients are elderly, and there are cases of patients having difficulty swallowing. Lyrica OD Tablets dissolve swiftly inside the mouth, making it an easy form for these patients to take, and are expected to lead to increased convenience when taking medicine.
Through Lyrica, Pfizer and Eisai will continue to contribute to improvement of quality of life in patients suffering from neuropathic pain and pain associated with fibromyalgia.
http://www.acnnewswire.com/topimg/Low_EisaiLyrica.jpg
Contact:
Corporate Communications
Pfizer Japan Inc.
Telephone: +81-3-5309-6644
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
| Eisai Related News |
|
| Thursday, 31 July 2025, 18:27 JST |
| Revenue of LEQEMBI(R) (Preliminary Basis) |
|
| Thursday, 31 July 2025, 9:30 JST |
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
|
| Thursday, 31 July 2025, 9:20 JST |
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
|
| Thursday, 31 July 2025, 9:10 JST |
| Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 |
|
| Tuesday, 29 July 2025, 9:01 JST |
| LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
|
| More news >> |
|
|
|
